Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Xceleron, Crystal Pharmatech in Bioavailability Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Xceleron, Crystal Pharmatech in Bioavailability Pact

Aims to improve early clinical development

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Xceleron, a provider of ultra-sensitive analytical technology to novel clinical designs, has partnered with Crystal Pharmatech, a China-based CRO, to offer drug developers early bioavailability data to optimize solid-state forms and formulations. The partnership will combine accelerator mass spectrometry (AMS) technology and expertise aimed at cost-effectively removing pharmacokinetic uncertainty by providing better early clinical and solid-state information.
 
“At Xceleron, we believe that technology can get life-changing drugs to people who need them, sooner and at a lower cost. This partnership will help our clients do that by efficiently and cost-effectively answering critical questions earlier,” said Dr. Michael Butler, chief executive officer of Xceleron.
 
“Having robust bioavailability and pharmacokinetic data at the outset provides a strong foundation for determining the best solid form and formulation,” said Dr. Alex Chen, chief executive officer of Crystal Pharmatech. “Each company brings significant expertise to the discussion of novel clinical outcomes.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics